Clin2
NCT06132698Possibly a fitRecruiting

Immunotherapy injected into spinal fluid for lung cancer that has spread to the brain lining

NSCLC Associated With Leptomeningeal Metastases

Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.

This trial tests giving an immunotherapy drug directly into the spinal fluid for people with non-small cell lung cancer that has spread to the lining of the brain or spinal cord. The goal is to see if this approach can help control the cancer while allowing you to continue other treatments you may already be taking.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
17 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • You have non-small cell lung cancer that has spread to the lining of the brain or spinal cord (called leptomeningeal metastases).
  • You are able to get around and take care of yourself, even if you need some help (ECOG score 0 to 4).
  • Your doctor expects you to live at least 4 more weeks.
  • You have adequate organ function, including normal blood counts, kidney function, and liver function.
  • You are willing to use birth control if needed, and are not pregnant or breastfeeding.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06431685Recruiting· Phase 1
Brain radiation, immunotherapy, and chemo for lung cancer spread

This trial tests a combination of low-dose radiation to the whole brain, immunotherapy, and chemotherapy given through a lumbar puncture. It is for people with lung cancer that has spread to the lining of the brain and has not responded to standard treatments.

Chengdu, Sichuan
NCT06296745Recruiting· Phase 2
Pemetrexed in spinal fluid for lung cancer that spread to brain lining

This trial tests a drug called pemetrexed, given directly into the fluid around the spinal cord (intrathecal), for people with lung cancer that has spread to the brain and spinal cord lining and is no longer controlled by the targeted therapy osimertinib.

Huizhou, Guangdong
NCT07778940Not yet recruiting· Phase 2
Chemotherapy through a brain port for lung cancer that has spread to the spinal fluid

This trial tests a chemotherapy drug called thiotepa, given through a small device placed under the scalp (Ommaya reservoir) that delivers the drug directly into the spinal fluid. It is for people with non-small cell lung cancer that has spread to the lining of the brain or spinal cord and who have stopped responding to certain targeted therapies.

Tianjin
NCT06440954Recruiting· Phase 2
Pemetrexed injected into spinal fluid for lung cancer that spread to brain lining

This study tests a treatment called intrathecal pemetrexed, which is chemotherapy given directly into the fluid around your brain and spine. It's for people with a specific type of lung cancer that has spread to the lining of the brain or spinal cord after targeted therapy stopped working.

Changsha, Hunan
NCT06663306Recruiting· Phase 1
Intrathecal pemetrexed and bevacizumab for lung cancer brain spread

This trial tests a treatment given directly into the fluid around the brain and spinal cord (intrathecal injection) using two drugs—pemetrexed and bevacizumab—for people with non-small cell lung cancer that has spread to that area (leptomeningeal metastases). It may be an option if your current treatment is no longer working.

Shanghai
NCT07702305Not yet recruiting· Phase 1
Sacituzumab Tirumotecan into spinal fluid for advanced lung cancer

This trial tests a new drug, sacituzumab tirumotecan, given directly into the spinal fluid. It is for people with a specific type of lung cancer (EGFR-mutant) that has spread to the lining of the brain or spinal cord and has stopped responding to standard targeted pills.

Hear when a new NSCLC Associated With Leptomeningeal Metastases trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.